Claim 1 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 2 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 3 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 4 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 5 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 6 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 7 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 8 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 9 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 10 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 11 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 12 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 13 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 14 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 15 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 16 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 17 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 18 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 19 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 20 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 21 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 22 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 23 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 24 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 25 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 26 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 27 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 28 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 29 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 30 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 31 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 32 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 33 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 34 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 35 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 36 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 37 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 38 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 39 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 40 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 41 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 42 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 43 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 44 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 45 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 46 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 47 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 48 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 49 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 50 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 51 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 52 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 53 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 54 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 55 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 56 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 57 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 58 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 59 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 60 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 61 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 62 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 63 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 64 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 65 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 66 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 67 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 68 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 69 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 70 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 71 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 72 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 73 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 74 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 75 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 76 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 77 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 78 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 79 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 80 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 81 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 82 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 83 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 84 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 85 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 86 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 87 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 88 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 89 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 90 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 91 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 92 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 93 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 94 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 95 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 96 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 97 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 98 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 99 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 100 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 101 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 102 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 103 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 104 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 105 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 106 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 107 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 108 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 109 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 110 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 111 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 112 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 113 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 114 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 115 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 116 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 117 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 118 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 119 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 120 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 121 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 122 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 123 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 124 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 125 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 126 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 127 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 128 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 129 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 130 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 131 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 132 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 133 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 134 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 135 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 136 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 137 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 138 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 139 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 140 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 141 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 142 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 143 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 144 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 145 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 146 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 147 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 148 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 149 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 150 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 151 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 152 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 153 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 154 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 155 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 156 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 157 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 158 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 159 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 160 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 161 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 162 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 163 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 164 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 165 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 166 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 167 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 168 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 169 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 170 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 171 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 172 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 173 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 174 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 175 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 176 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 177 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 178 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 179 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 180 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 181 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 182 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 183 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 184 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 185 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 186 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 187 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 188 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 189 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 190 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 191 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 192 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 193 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 194 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 195 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 196 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 197 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 198 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 199 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 200 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 201 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 202 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 203 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 204 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 205 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 206 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 207 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 208 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 209 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 210 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 211 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 212 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 213 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 214 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 215 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 216 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 217 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 218 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 219 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 220 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 221 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 222 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 223 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 224 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 225 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 226 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 227 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 228 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 229 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 230 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 231 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 232 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 233 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 234 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 235 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 236 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 237 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 238 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 239 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 240 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 241 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 242 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 243 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 244 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 245 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 246 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 247 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 248 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 249 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 250 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 251 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 252 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 253 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 254 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 255 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 256 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 257 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 258 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 259 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 260 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 261 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 262 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 263 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 264 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 265 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 266 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 267 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 268 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 269 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 270 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 271 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 272 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 273 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 274 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 275 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 276 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 277 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 278 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 279 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 280 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 281 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 282 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 283 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 284 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 285 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 286 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 287 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 288 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 289 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 290 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 291 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 292 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 293 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 294 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 295 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 296 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 297 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 298 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 299 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 300 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 301 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 302 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 303 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 304 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 305 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 306 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 307 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 308 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 309 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 310 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 311 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 312 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 313 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 314 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 315 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 316 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 317 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 318 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 319 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 320 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 321 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 322 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 323 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 324 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 325 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 326 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 327 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 328 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 329 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 330 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 331 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 332 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 333 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 334 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 335 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 336 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 337 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 338 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 339 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 340 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 341 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 342 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 343 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 344 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 345 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 346 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 347 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 348 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 349 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 350 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 351 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 352 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 353 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 354 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 355 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 356 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 357 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 358 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 359 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 360 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 361 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 362 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 363 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 364 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 365 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 366 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 367 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 368 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 369 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 370 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 371 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 372 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 373 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 374 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 375 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 376 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 377 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 378 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 379 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 380 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 381 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 382 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 383 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 384 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 385 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 386 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 387 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 388 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 389 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 390 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 391 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 392 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 393 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 394 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 395 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 396 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 397 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 398 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 399 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 400 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.